MedTrace Logo

Glioblastoma Targeted Treatment Option Maximization by WGS

NCT05186064 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2024-05-08

No results posted yet for this study

Summary

In Dutch centers performing neurosurgery on and/or treating GBM, all recurrent GBM patients are discussed in local tumor boards and this setup will be used to effectively identify possible GLOW study candidates. 160 patients that will undergo re-resection in the GLOW study will be presented with WGS results leading to added treatment options.

Conditions

Interventions

DIAGNOSTIC_TEST

whole genome sequencing

whole genome sequencing will be performed on tumor material after re-resection per standard of care

Sponsors & Collaborators

  • Amsterdam University Medical Center

    collaborator OTHER

  • The Netherlands Cancer Institute

    collaborator OTHER

  • The Elisabeth-TweeSteden Hospital

    collaborator OTHER

  • Erasmus Medical Center

    collaborator OTHER

  • Medical Center Haaglanden

    collaborator OTHER

  • Isala

    collaborator OTHER

  • Leiden University Medical Center

    collaborator OTHER

  • Maastricht University Medical Center

    collaborator OTHER

  • Medisch Spectrum Twente

    collaborator OTHER

  • Radboud University Medical Center

    collaborator OTHER

  • University Medical Center Groningen

    collaborator OTHER

  • UMC Utrecht

    lead OTHER

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-25
Primary Completion
2024-07-01
Completion
2025-07-01

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05186064 on ClinicalTrials.gov